- Home
- AVTX vs RVPH Comparison
AVTX vs RVPH Comparison
Compare AVTX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- RVPH
- Stock Information
- Founded
- AVTX 2011
- RVPH 2006
- Country
- AVTX United States
- RVPH United States
- Employees
- AVTX N/A
- RVPH N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- RVPH Health Care
- Exchange
- AVTX Nasdaq
- RVPH Nasdaq
- Market Cap
- AVTX 138.8M
- RVPH 30.1M
- IPO Year
- AVTX 2015
- RVPH N/A
- Fundamental
- Price
- AVTX $11.33
- RVPH $0.40
- Analyst Decision
- AVTX Strong Buy
- RVPH Strong Buy
- Analyst Count
- AVTX 9
- RVPH 5
- Target Price
- AVTX $30.14
- RVPH $5.20
- AVG Volume (30 Days)
- AVTX 188.1K
- RVPH 1.3M
- Earning Date
- AVTX 11-06-2025
- RVPH 11-13-2025
- Dividend Yield
- AVTX N/A
- RVPH N/A
- EPS Growth
- AVTX N/A
- RVPH N/A
- EPS
- AVTX N/A
- RVPH N/A
- Revenue
- AVTX $441,000.00
- RVPH N/A
- Revenue This Year
- AVTX N/A
- RVPH N/A
- Revenue Next Year
- AVTX N/A
- RVPH N/A
- P/E Ratio
- AVTX N/A
- RVPH N/A
- Revenue Growth
- AVTX N/A
- RVPH N/A
- 52 Week Low
- AVTX $3.39
- RVPH $0.30
- 52 Week High
- AVTX $16.00
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- AVTX 62.61
- RVPH 34.75
- Support Level
- AVTX $9.54
- RVPH $0.50
- Resistance Level
- AVTX $12.41
- RVPH $0.47
- Average True Range (ATR)
- AVTX 1.05
- RVPH 0.03
- MACD
- AVTX -0.10
- RVPH -0.01
- Stochastic Oscillator
- AVTX 71.28
- RVPH 14.30
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.